| APOA5 |
| LOCUS ID | 116519 | ||||||||||||||||
| GENE_SYMBOL | APOA5 | ||||||||||||||||
| GENE NAME | apolipoprotein A-V | ||||||||||||||||
| SYNONYMNS | RAP3, APOAV | ||||||||||||||||
| CHROMOSOME | 11 | ||||||||||||||||
| HOMOLOGENE ID | 14197 |
| microRNAs | NA | NA |
| GENE SUMMARY |
|---|
| The protein encoded by this gene is an apolipoprotein that plays an important role in regulating the plasma triglyceride levels, a major risk factor for coronary artery disease. It is a component of high density lipoprotein and is highly similar to a rat protein that is upregulated in response to liver injury. Mutations in this gene have been associated with hypertriglyceridemia and hyperlipoproteinemia type 5. This gene is located proximal to the apolipoprotein gene cluster on chromosome 11q23. |
| OBSERVATIONS |
|---|
| Complication | Evidence | PMID |
| Cardiovascular | 1. In conclusion, because various genes, LDLR, CETP, APOA5, Apo E, Apo B, and Apo A-I, are associated with the precipitation of CAD associated with T2DM, a personalized diet-gene intervention therapy may be advocated to reduce the disease precipitation. | 25470794 |
| Atherosclerosis | 1. In a dyslipemic population, genetic variants of APOA5 modulate lipoprotein subclass distributions, inducing an atherogenic profile associated with IMT defined subclinical atherosclerosis. | 25770687 |
| Dyslipidemia | 1. In high cardiovascular risk patients (e.g., patients with metabolic syndrome or type 2 diabetes), APOA5 variants elevate TG levels and shift the entire lipoprotein subclass distribution toward atherogenic dyslipidemia. | 28500476 |